Portfolio and pipeline
Multiparticulate pellet formulations.
Semi-finished, ready-to-fill pellet dosage forms. Search by molecule, or separate commercial manufacture from the development pipeline.
Loading the portfolio…
Portfolio and pipeline
Semi-finished, ready-to-fill pellet dosage forms. Search by molecule, or separate commercial manufacture from the development pipeline.
Loading the portfolio…
Showing 25 validated formulations
Active Molecule: Esomeprazole Magnesium
Enteric coated pellets under development pipeline for gastro-resistant proton pump inhibition.
Validated drug load
8.5%, 10.0%, 15.0%, 20.0%, 22.0% & 22.5% w/w
Standards: IP / USP Candidate
Active Molecule: Dexlansoprazole
Dual delayed-release multiparticulate technology in development pipeline.
Validated drug load
20.0% & 22.5% w/w
Standards: In-house Development Specification
Active Molecule: Dabigatran Etexilate Mesylate
Immediate release multiparticulate pellets under development pipeline.
Validated drug load
35.0% & 40.0% w/w
Standards: USP / In-house
Active Molecule: Duloxetine Hydrochloride
Enteric coated multiparticulates formulated with an acid-protective enteric shell under development pipeline.
Validated drug load
17.0%, 20.0% & 22.5% w/w
Standards: USP / IP Candidate
Active Molecule: Tamsulosin Hydrochloride
Micro-dose sustained release multiparticulates with membrane diffusion coating under development pipeline.
Validated drug load
0.2%, 0.4%, 0.12% & 0.16% w/w
Standards: IP / USP Candidate
Active Molecule: Venlafaxine Hydrochloride
Extended release multiparticulates utilizing membrane diffusion barriers under development pipeline.
Validated drug load
32.0%, 33.0%, 36.0% & 40.0% w/w
Standards: USP / IP Candidate
Active Molecule: Itopride Hydrochloride
Sustained release pellets under development pipeline.
Validated drug load
60.0% w/w
Standards: In-house Specification
Active Molecule: Diclofenac Sodium
Sustained release multiparticulate pellets with diffusion barrier coating under development pipeline.
Validated drug load
35.0%, 40.0% & 50.0% w/w
Standards: IP / BP Candidate
Active Molecule: Mebeverine Hydrochloride
Sustained release pellets with diffusion barrier coating under development pipeline.
Validated drug load
40.0%, 50.0% & 80.0% w/w
Standards: BP / IP Candidate
Active Molecule: Lansoprazole
Gastro-resistant enteric coated pellets for proton pump inhibition.
Validated drug load
8.5%, 9.5%, 11.2%, 12.5% & 22.5% w/w
Standards: USP / IP Candidate
Active Molecule: Orlistat
Immediate release pellets under development pipeline.
Validated drug load
25.0% & 50.0% w/w
Standards: USP Candidate
Active Molecule: Chlorpheniramine Maleate
Antihistamine multiparticulates formulated for combination products under development.
Validated drug load
4.0% w/w
Standards: IP Candidate
Active Molecule: Ketoprofen
Sustained-release NSAID multiparticulates under development pipeline.
Validated drug load
60.0% w/w
Standards: BP / IP Candidate
Active Molecule: Levosulpiride
Sustained release pellets under development pipeline for gastrointestinal motility blends.
Validated drug load
40.0% w/w
Standards: In-house Specification
Active Molecule: Sucralfate
High drug-load immediate release pellets under development pipeline.
Validated drug load
70.0% w/w
Standards: USP / IP Candidate
Active Molecule: Atorvastatin (10mg/20mg) & Clopidogrel Bisulphate (75mg)
Cardiovascular dual-drug multiparticulates combining antiplatelet and statin pellets into a single capsule fill.
Validated drug load
10mg/75mg & 20mg/75mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Esomeprazole EC (20mg/40mg) & Domperidone SR (30mg)
Gastro-resistant PPI with sustained-release prokinetic multiparticulates for capsule filling under development.
Validated drug load
20mg/30mg & 40mg/30mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Pantoprazole Sodium EC (20mg/40mg) & Domperidone SR (30mg)
Stabilized enteric pantoprazole combined with sustained release domperidone pellets under development.
Validated drug load
20mg/30mg & 40mg/30mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Pantoprazole EC (40mg) & Itopride HCl SR (150mg)
Enteric coated proton pump inhibitor combined with sustained release prokinetic pellets under development.
Validated drug load
40mg/150mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Pantoprazole EC (40mg) & Levosulpiride SR (75mg)
Enteric coated PPI combined with sustained-release prokinetic multiparticulates under development.
Validated drug load
40mg/75mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Rabeprazole Sodium EC (20mg) & Domperidone SR (30mg)
Enteric PPI blended with sustained release antiemetic pellets for capsule filling under development.
Validated drug load
20mg/30mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Rabeprazole Sodium EC (20mg) & Aceclofenac SR (100mg/200mg)
Gastro-protected NSAID dual system designed to mitigate ulcerogenic risks of chronic anti-inflammatory therapy.
Validated drug load
20mg/100mg & 20mg/200mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Rabeprazole Sodium EC (20mg) & Levosulpiride SR (75mg)
Enteric rabeprazole combined with sustained levosulpiride multiparticulates.
Validated drug load
20mg/75mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Rabeprazole Sodium EC (20mg) & Itopride HCl SR (150mg)
Prokinetic and PPI dual multiparticulates in fixed-ratio capsule fills.
Validated drug load
20mg/150mg dose equivalent
Standards: In-house B2B Standard
Active Molecule: Tamsulosin HCl SR (0.4mg) & Dutasteride IR (0.5mg)
Urological combo multiparticulates uniting alpha-blocker sustained release with 5-alpha reductase inhibitor.
Validated drug load
0.4mg/0.5mg dose equivalent
Standards: In-house B2B Standard